The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice

Journal of Bone and Mineral Metabolism

Volumn 30, Issue 6, 2012, Pages 630-637

  Wang, Chun ^b   Li, Hong ^a   Chen, Sheng Guang ^b   He, Jin Wei ^b   Sheng, Chun Jun ^a   Cheng, Xiao Yun ^a   Qu, Shen ^a   Wang, Ke Sheng ^a   Lu, Mei Ling ^a   Yu, Yong Chun ^a  

^a TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Diabetes mellitus; Insulin sensitizer; Metformin; Rosiglitazone; Skeletal effect

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; FATTY ACID BINDING PROTEIN 4; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TRANSCRIPTION FACTOR RUNX2;

ADIPOCYTE; ADIPOGENESIS; ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; BONE MASS; BONE MINERAL; BONE MORPHOGENETIC PROTEIN 2 GENE; BONE STRUCTURE; CELL COUNT; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; FAT CONTENT; FATTY ACID BINDING PROTEIN 4 GENE; FEMALE; GENE EXPRESSION REGULATION; INSULIN RESISTANCE; MARKER GENE; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RUNX RELATED TRANSCRIPTION FACTOR 2 GENE; TRABECULAR BONE; WEIGHT GAIN;

ANIMALS; BLOOD GLUCOSE; BONE DENSITY; BONE MORPHOGENETIC PROTEIN 2; CORE BINDING FACTOR ALPHA 1 SUBUNIT; FATTY ACID-BINDING PROTEINS; FEMALE; FEMUR; INSULIN RESISTANCE; METFORMIN; MICE; MICE, INBRED C57BL; THIAZOLIDINEDIONES;

EID: 84875808933     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-012-0374-0     Document Type: Article

References (30)

1. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J (2010) Prevalence of diabetes among men and women in China. N Engl J Med 362:1090-1101
2. Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes: a meta-analysis. Osteoporos Int 18:427-444
3. Janghorbani M, Van Dam RM, Willett WC, Hu FB (2007) Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 166:495-505
4. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G (2008) Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31:845-851
5. Aubert RE, Herrera V, Chen W, Haffner SM, Pendergrass M (2010) Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab 12:716-721
6. Douglas IJ, Evans SJ, Pocock S, Smeeth L (2009) The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med 6:e1000154
7. Berberoglu Z, Yazici AC, Demirag NG (2010) Effects of rosiglitazone on bone mineral density and remodelling parameters in postmenopausal diabetic women: a 2-year follow-up study. Clin Endocrinol (Oxf) 73:305-312
8. Loke YK, Singh S, Furberg CD (2009) Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 180:32-39
9. Jones SG, Momin SR, Good MW, Shea TK, Patric K (2009) Distal upper and lower limb fractures associated with thiazolidinedione use. Am J Manag Care 15:491-496
10. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401-406
11. Viccica G, Francucci CM, Marcocci C (2010) The role of PPARgamma for the osteoblastic differentiation. J Endocrinol Invest 33:9-12
12. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B (2007) Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148:2669-2680
13. Adami S (2009) Bone health in diabetes: considerations for clinical management. Curr Med Res Opin 25:1057-1072
14. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T (2008) Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun 375:414-419
15. Srinivasan K, Ramarao P (2007) Animal models in type 2 diabetes research: an overview. Indian J Med Res 125:451-472
16. Bloebaum RD, Willie BM, Mitchell BS, Hofmann AA (2007) Relationship between bone ingrowth, mineral apposition rate, and osteoblast activity. J Biomed Mater Res A 81:505-514
17. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL (2005) Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146:1226-1235
18. Ma L, Ji JL, Ji H, Yu X, Ding LJ, Liu K, Li YQ (2010) Telmisartan alleviates rosiglitazone-induced bone loss in ovariectomized spontaneous hypertensive rats. Bone (NY) 47:5-11
19. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
20. Bustin SA (2000) Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 25:169-193
21. Toulis KA, Goulis DG, Anastasilakis AD (2009) Thiazolidinedione use and the risk of fractures. CMAJ 180:841-842 (author reply 842-843)
22. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR (2009) Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 32:187-202
23. Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP (2008) Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 93:1696-1701
24. Mai Q, Zhang Z, Xu S, Lu M, Zhou R, Zhao L, Jia C, Wen Z, Jin D, Bai X (2011) Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem 112:2902-2909
25. Jang WG, Kim EJ, Bae IH, Lee KN, Kim YD, Kim DK, Kim SH, Lee CH, Franceschi RT, Choi HS, Koh JT (2011) Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2. Bone (NY) 48:885-893
26. Zhen D, Chen Y, Tang X (2010) Metformin reverses the deleterious effects of high glucose on osteoblast function. J Diabetes Complicat 24:334-344
27. Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Heras M, Masana L (2007) Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis 195:e150-e158
28. Sottile V, Seuwen K (2000) Bone morphogenetic protein-2 stimulates adipogenic differentiation of mesenchymal precursor cells in synergy with BRL 49653 (rosiglitazone). FEBS Lett 475:201-204
29. Chen D, Ji X, Harris MA, Feng JQ, Karsenty G, Celeste AJ, Rosen V, Mundy GR, Harris SE (1998) Differential roles for bone morphogenetic protein (BMP) receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages. J Cell Biol 142:295-305
30. Zhang M, Zhou SH, Zhao S, Li XP, Liu LP, Shen XQ (2008) Pioglitazone can downregulate bone morphogenetic protein-2 expression induced by high glucose in human umbilical vein endothelial cells. Pharmacology 81:312-316